09:04 AM EDT, 09/10/2025 (MT Newswires) -- Actuate Therapeutics ( ACTU ) said Wednesday it has priced an underwritten public offering of about 2.1 million shares at $7 each for gross proceeds of roughly $15 million.

The company said it has granted underwriters a 30-day option to buy up to 321,428 additional shares, adding that the offering will likely close on Thursday.

Net proceeds are expected to be used for working capital and general corporate purposes, Actuate Therapeutics ( ACTU ) said.

The company's shares were down more than 21% in recent Wednesday premarket activity.